Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 8/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752889 | 0.82 | FAAH (0.50) | FAAH | |
| SCHEMBL3747530 | 0.80 | FAAH (0.52) | FAAH | |
| SCHEMBL3747918 | 0.74 | FAAH (0.43) | FAAH | |
| SCHEMBL3749052 | 0.74 | FAAH (0.43) | FAAHIDH1 | |
| SCHEMBL28722124 | 0.72 | MAPT (0.52) | SMN1; SMN2LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL4933877 | 0.71 | BCHE (0.53) | SMN1; SMN2LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL3753147 | 0.71 | ACKR3 (0.45) | SMN1; SMN2LMNAFAAHUSP2KDM4E | |
| SCHEMBL4929684 | 0.70 | MAPT (0.50) | SMN1; SMN2LMNAALDH1A1MAPTKMT2A | |
| SCHEMBL3749029 | 0.69 | FAAH (0.53) | FAAH | |
| SCHEMBL13052551 | 0.69 | FAAH (0.57) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | claimed |
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | FAAH, FAAH2, APEH | SMN1; SMN2 875/4885LMNA 3891/4885FAAH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.